Symbio Signs Five-Year Agreement for OmniComm’s TrialMaster
Symbio LLC, a client-focused, full-service clinical research organization, has signed a five-year contract with OmniComm Systems, Inc., a global provider of clinical data management technology. Under the agreement, Symbio will use OmniComm’s TrialMaster version 5 to develop and manage clinical study databases.
Additonally, in 2018, Symbio launched its European operations to support clients with global trials. With the opening of that division, OmniComm’s data center in Europe became a major factor in the selection of TrialMaster. Symbio cited the stability and performance of OmniComm’s EDC technology, TrialMaster’s randomization capability, and the ability to create submission-ready CRFs, ad hoc reports, and customized reports to address sponsors’ needs and requests as contributing factors to its decision.
“We are honored and thrilled that the Symbio management team has selected OmniComm’s TrialMaster platform with its advanced EDC and eSource technology to enhance the services provided to their Sponsor clients,” said Kuno van der Post, PhD, chief commercial officer, OmniComm Systems. “To have another key global CRO choose TrialMaster is very rewarding.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
